Median Technologies

Equities

ALMDT

FR0011049824

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris Other stock markets 11:38:52 2024-07-15 am EDT			5-day change	1st Jan Change
2.24 ^EUR	-5.49%		-19.71%	-52.84%

May. 22	Median: service contract with a major pharmaceutical company	CF
May. 21	Median Technologies Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company	CI

Median Technologies : Calendrier de communication financière du second semestre 2024

July 11, 2024 at 11:49 am EDT

Median Technologies : Calendrier de communication financière du second semestre 2024

11 Jul 2024 17:45 CEST

Issuer

MEDIAN TECHNOLOGIES

Regulatory News:

Median Technologies (FR0011049824, ALMDT, éligible au plan PEA/PME, "Median" ou "la Société")annonce la date de publication de ses résultats semestriels 2024 et de ses performances business pour le troisième trimestre 2024.

Publication	Date
Résultats semestriels 2024 Performances T3 2024	24 octobre 2024*

*Diffusion après clôture des marchés

A propos de Median Technologies : Pionnière dans les solutions et services d'imagerie innovants, Median Technologies exploite les technologies de pointe d'Intelligence Artificielle pour augmenter la précision des diagnostics précoces et des traitements de nombreux cancers. Les offres de Median, iCRO pour l'analyse et la gestion des images médicales dans les essais cliniques en oncologie et eyonis™, suite de logiciels dispositifs médicaux basés sur les technologies de l'IA, permettent aux sociétés biopharmaceutiques et aux cliniciens de faire progresser les soins aux patients et d'accélérer le développement de nouvelles thérapies. La société française, également présente aux Etats-Unis et en Chine, est cotée sur le marché Euronext Growth (ISIN : FR0011049824, MNEMO : ALMDT). Median Technologies est éligible au PEA-PME. Plus d'informations sur www.mediantechnologies.com

Consultez la version source sur businesswire.com :https://www.businesswire.com/news/home/20240711446520/fr/

Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Presse - ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

Investisseurs - ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com

Source

MEDIAN TECHNOLOGIES

Provider

BusinessWire

Company Name

MEDIAN TECHNOLOGIES

ISIN

FR0011049824

Symbol

ALMDT

Market

Euronext Growth

Attachments

Original Link
Permalink

Disclaimer

Median Technologies SA published this content on 11 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 July 2024 15:48:04 UTC.

Latest news about Median Technologies

Median: service contract with a major pharmaceutical company	May. 22	CF
Median Technologies Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company	May. 21	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
European Investment Bank OKs Median Technologies' Draw Down of Final EUR8.5 Million Loan Tranche	Dec. 28	MT
Median: final tranche of EIB loan approved	Dec. 27	CF
Median: an alliance in cancer biomarkers	Dec. 15	CF
Median Technologies and Pasrel-Imagerie Join Forces to Deliver Smart Imaging Biomarkers Supporting the Development of New Oncology Drugs in Precision Medicine	Dec. 14	CI
Median: diagnostics portfolio renamed 'eyonis	Nov. 27	CF
Median Technologies Rebrands Software-as-Medical-Devices Business as Eyonis	Nov. 27	MT
Median Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-18	CI
Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress	23-10-17	CI
Median Technologies: appointment to the Board of Directors	23-10-11	CF
Median Technologies Appoints Ben Mcdonald to Its Board of Directors	23-10-10	CI
Median Technologies SA(ENXTPA:ALMDT) dropped from S&P Global BMI Index	23-09-18	CI
Median Technologies SA announced that it has received ?10 million in funding from Lake Bridge Capital Inc	23-07-18	CI
Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD	23-07-17	CI
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines....	23-07-13
Median Technologies SA announced that it expects to receive â‚¬10 million in funding from Lake Bridge Capital Inc	23-07-11	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Median Technologies to Present New and Breakthrough Results for its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device	23-02-28	CI
Global markets live: Adecco, Bayer, Chevron, Target, Tesla...	23-02-28
Median: preliminary submissions phase finalized in the USA	23-02-28	CF
Median Technologies Announces Completion of the Q-Submission Phase with the FDA for Its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device	23-02-27	CI
Median Technologies SA Announces Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-01-19	CI

Chart Median Technologies

Duration

Period

More charts

Company Profile

Median Technologies offers innovative imaging solutions and services to improve healthcare for all. The group uses the power of phenomic imaging to contribute to the emergence of new therapies and treatment strategies for patients. Its solutions, «iSee» for the image management in oncology trials and «eyonisTM» (formerly iBiopsy®), its phenomic imaging platform, combined with the expertise of its teams are an essential part to the discovery of new drugs and diagnostic tools to monitor diseases and evaluate the response of patients to their therapy. Median Technologies is helping biopharmaceutical companies and healthcare professionals quickly and accurately introduce new treatments to patients who need them, with a view to reducing overall costs of care. Provision of services accounts for all net sales. Net sales are distributed geographically as follows: China (41.6%), the United States and Canada (30.4%), Europe and other (28%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-10-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Median Technologies

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.24 EUR

Average target price

16.92 EUR

Spread / Average Target

+655.58%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
MEDIAN TECHNOLOGIES	-52.84%	47.54M
THERMO FISHER SCIENTIFIC	+2.62%	209B
DANAHER CORPORATION	+6.44%	183B
INTUITIVE SURGICAL, INC.	+29.61%	158B
BOSTON SCIENTIFIC CORPORATION	+34.96%	114B
SIEMENS HEALTHINEERS AG	+3.84%	67.29B
EDWARDS LIFESCIENCES CORPORATION	+17.38%	54.83B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.51%	46.88B
AGILENT TECHNOLOGIES, INC.	-5.77%	38.58B
GE HEALTHCARE TECHNOLOGIES INC.	+3.71%	36.65B

Other Advanced Medical Equipment & Technology